May be a person thinking about the rule

Июль 25, 2022

Главная
Маркетинг
May be a person thinking about the rule

Содержание

2. Figure 2 (page 20): An illustration that combines the face of the unicorn and the body
3. Figure 4 (page 23): Map of the world showing where early biopharma manufacturers emerged
4. Figure 5 (page 25): An illustrative label of a biopharma product from early days of the
5. Figure 6 (Page 31): A modern label from pharma industry – showing the kind of information
6. Figure 7 (page 36): Graph showing how insurance based payments took off in mid-90s.
7. Figure 8 (page 36): Annual US revenue of biopharmaceuticals – from 1985 - 2015
8. Figure 9 (page 38): Image of a unicorn with wings stationary, jet propulsion behind, and blockbusters
9. Figure 10 (page 41): Image of unicorn with jet propulsion dying down, wings beginning to flap,
10. Figure 11 (page 61): Cartoon/s showing disruption of US healthcare, all stakeholders scrambling
11. ADJACENT BREAKTHROUGH Fully Participate in Value Based Care Zero Downtime for Patients Strengthen the Core Business
12. Figure 13 (page 74) Current: R = P x v Future: R = p x V
13. Figure 14 (page 75): Relative industry margins declining By Berndt’s estimates, pharmaceutical products released between 2005
14. Figure 15 (page 76): Image of a person sitting on a plane, smart pill in stomach,
15. Level 0: No Automation Smart Capability: None. Provider involvement: Prescribing & administering. Patient Involvement: Taking medication.
16. ADJACENT BREAKTHROUGH Fully Participate in Value Based Care Zero Downtime for Patients Reverse the Revenue Equation
17. Figure 18 (page 89): Image of a unicorn taking off at warp speed (star wars kind
18. Figure 19 (page 95): combination of the 80-80 rule image from figure 1 and the 4
19. Figure 20 (page 100): New Breed of Leaders People following leader vs. leader in the center
20. Figure 21 (page 106) Talent Mix cartoon 6 roles – Innovation leader Idea generators Technical experts
21. Figure 22 (page 110): “Embrace the need, money will follow” and “outside in first, inside out
22. Figure 23: Page 126:Image of a TV screen with red yellow green faces I like the
23. Figure 24 (page 130): Instead of the public place, call it hybrid existence. In the middle,
25. Скачать презентацию

Слайд 2

Figure 2 (page 20): An illustration that combines the face of

the unicorn and the body representing biopharma industry, flapping its wings to signify take off and growth

Слайд 3

Figure 4 (page 23): Map of the world showing where early

biopharma manufacturers emerged

Слайд 4

Figure 5 (page 25): An illustrative label of a biopharma product

from early days of the industry

Слайд 5

Figure 6 (Page 31): A modern label from pharma industry –

showing the kind of information included (something better than below)

Слайд 6

Figure 7 (page 36): Graph showing how insurance based payments took

off in mid-90s.

Слайд 7

Figure 8 (page 36): Annual US revenue of biopharmaceuticals – from

1985 - 2015

Слайд 8

Figure 9 (page 38): Image of a unicorn with wings stationary,

jet propulsion behind, and blockbusters in the jet stream

Image of unicorn

Слайд 9

Figure 10 (page 41): Image of unicorn with jet propulsion dying

down, wings beginning to flap, but showing a lower trajectory of flight + graph below showing average revenues per product

Source: https://www.forbes.com/sites/peterubel/2016/07/29/is-the-golden-era-of-pharmaceutical-profits-over/#494789c17207

Слайд 10

Figure 11 (page 61): Cartoon/s showing disruption of US healthcare, all

stakeholders scrambling

Слайд 11

ADJACENT
BREAKTHROUGH
Fully Participate in Value Based Care
Zero Downtime for Patients
Strengthen the Core

Business Model

Monetize Core Capabilities

CORE

Develop “Smart” Products

BUSINESS MODEL

SAME

DIFFERENT

INNOVATION

PRODUCT FOCUS

PRODUCT+ SERVICE
FOCUS

Reverse the Revenue Equation

Figure 12 (page 72)

The Y-axis displays opportunities across the three forms of innovation described in the prior section. The X-axis displays the evolution of a company’s overall business model over time which encompasses where and how it generates revenue and the way it engages with the market through its customer engagement or commercial model.

Слайд 12

Figure 13 (page 74)
Current: R = P x v
Future: R =

p x V
Superimposed on -
Current: Image of the world with US, EU and Japan shown as big compared to Asia, LatAm
Future: A normal map of the world

Слайд 13

Figure 14 (page 75): Relative industry margins declining
By Berndt’s estimates, pharmaceutical

products released between 2005 and 2009 barely broke even:

Source: https://www.forbes.com/sites/peterubel/2016/07/29/is-the-golden-era-of-pharmaceutical-profits-over/#494789c17207

Слайд 14

Figure 15 (page 76): Image of a person sitting on a plane,

smart pill in stomach, throwing out data such as cold, thirsty, hungry, sleepy – being received by airline stewards who are bringing water, blankets, dimming lights, bring food in response….

Слайд 15

Level 0: No Automation
Smart Capability: None. Provider involvement: Prescribing & administering.

Patient Involvement: Taking medication. Manufacturer Involvement: Pharmacovigilance through spontaneous reporting. Examples: All self-administered prescription products.

Level 1: Passive Medication Adherence
Smart Capability: Passive Medication Reminders. Provider involvement: Prescribing & administering. Patient Involvement: Taking medication. Manufacturer Involvement: Pharmacovigilance, adherence messaging and monitoring at population level. Examples: Smart Pill Bottles & Dispensers

Level 2: Active Medication Adherence
Smart Capability: Ingested Medication Reminders that alert patients when medicine concentration falls below a threshold within the body. Provider involvement: Prescribing & administering. Patient Involvement: Taking medication. Manufacturer Involvement: Pharmacovigilance. Examples: Otsuka & Proteus Technologies combination product (Abilify + smart chip)

Level 3: Assisted Dosing
Smart Capability: Ingested Medication alerts patients and providers when medicine concentration falls below a threshold within the body, side effects and clinical efficacy and effectiveness. Provider involvement: Prescribing, administering., monitoring and adjusting. Patient Involvement: Taking medication and active engagement with provider. Manufacturer Involvement: Enable Patient Provider Dialog. Active Recommendations. Pharmacovigilance. Examples: None

Level 4: Smart Dosing
Smart Capability: Controlled release of ingested medication concentration based on real-time monitoring of side effects, clinical efficacy and effectiveness. Provider involvement: Prescribing, administering, monitoring and adjusting. Patient Involvement: Taking medication. Manufacturer Involvement: Enable Patient Provider Dialog. Active Recommendations. Pharmacovigilance. Examples: None

Level 5: Healthy Time
Smart Capability: Guarantee of healthy time through active , remote management.. Provider involvement: Part of manufacturer service. Manufacturer Involvement: Enable Patient Provider Dialog. Active Recommendations. Pharmacovigilance. Patient Involvement: Taking medication. Examples: None

RKJH 2017 Standards to define levels of “smart” features in therapeutics that can enable manufacturers, regulators, payers, providers and patients create approval, administration and reimbursement policy frameworks and drive evolution of “smart therapeutics.” – © Ruchin Kansal & Jeff Huth. 2017

Smart Therapeutics

Driverless Cars

Figure 16 (page 80)

Слайд 16